Results of a randomized, multicenter phase II trial (ALK in Lung Cancer Trial of AP26113 [ALTA], NCT02094573) supported the initial approval of brigatinib in advanced ALK‐positive (ALK+) NSCLC that progressed on crizotinib.4, 5. This evidence concerns the gene ALK and lung cancer.